Reaction

Coronary Arterial Stent Insertion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,995 reports · 103 co-occurring drugs

As of the last recalculation, Coronary Arterial Stent Insertion appears in 4,995 FAERS reports alongside 103 co-occurring drug terms. The strongest observed disproportionality signal is RANOLAZINE (PRR 37.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranolazine	93	37.8	38.1
Clopidogrel	936	24.0	24.1
Nitroglycerin	236	19.2	19.3
Prasugrel Hydrochloride	44	18.2	18.3
Isosorbide Dinitrate	52	11.2	11.2
Quinapril Hydrochloride	18	9.5	9.6
Ticagrelor	67	8.9	8.9
Aspirin	905	8.3	8.4
Aspirin 81 Mg	858	8.2	8.2
Aspirin 325 Mg	855	8.2	8.2
Clopidogrel Bisulfate	184	7.7	7.8
Amlodipine Besylate And Benazepril Hydrochloride	17	7.7	7.7
Metoprolol Succinate	149	7.4	7.4
Ezetimibe And Simvastatin	25	6.9	6.9
Carvedilol	197	6.3	6.3
Risankizumab-Rzaa	114	5.9	5.9
Losartan Potassium And Hydrochlorothiazide	16	5.8	5.8
Metoprolol Tartrate	352	5.7	5.7
Icosapent Ethyl	11	5.4	5.4
Isosorbide Mononitrate	26	5.2	5.3
Insulin Human	48	5.1	5.1
Atenolol	148	4.7	4.7
Metoprolol	267	4.6	4.6
Nintedanib	34	4.5	4.5
Bosentan	54	4.5	4.5
Lisinopril And Hydrochlorothiazide	11	4.5	4.5
Metoroprolol Tartrate	70	4.5	4.5
Metoprolol Tartrate Injection	197	4.5	4.5
Lisinopril	310	4.4	4.4
Diltiazem Hydrochloride	36	4.4	4.4
Human Insulin	13	4.3	4.3
Valsartan And Hydrochlorothiazide	14	4.3	4.3
Digoxin	72	4.2	4.2
Fluticasone Propionate And Salmeterol	40	4.0	4.0
Ezetimibe	71	4.0	4.0
Enalapril Maleate	23	3.9	3.9
Evolocumab	143	3.8	3.8
Valsartan	93	3.7	3.7
Atorvastatin Calcium	211	3.7	3.7
Olmesartan Medoxomil	31	3.6	3.6
Upadacitinib	69	3.6	3.6
Amlodipine Besylate	123	3.6	3.6
Rosuvastatin	163	3.4	3.4
Metolazone	9	3.3	3.3
Glyburide	18	3.1	3.1
Nebivolol Hydrochloride	25	3.1	3.1
Furosemide	286	3.1	3.1
Insulin Aspart	48	3.0	3.0
Gemfibrozil	11	3.0	3.0
Amlodipine Besylate And Valsartan	8	3.0	3.0
Metoprolol Succinate Er Tablets	44	3.0	3.0
Felodipine Extended-Release Tablets	8	2.9	2.9
Felodipine	8	2.9	2.9
Ibrutinib	56	2.9	2.9
Pioglitazone	30	2.9	2.9
Glipizide	41	2.8	2.8
Simvastatin	158	2.7	2.7
Testosterone	15	2.7	2.7
Losartan Potassium	50	2.7	2.7
Sitagliptin	45	2.6	2.6
Fluticasone Furoate And Vilanterol Trifenatate	22	2.6	2.6
Doxazosin	17	2.5	2.5
Sitagliptin And Metformin Hydrochloride	13	2.5	2.5
Chlorthalidone	7	2.5	2.5
Pancrelipase	23	2.5	2.5
Sildenafil Powder,	21	2.5	2.5
Lovastatin	15	2.4	2.4
Macitentan	39	2.4	2.4
Bimekizumab	12	2.4	2.4
Metformin Hcl	31	2.3	2.3
Alirocumab	14	2.3	2.3
Umeclidinium	5	2.3	2.3
Abiraterone	7	2.1	2.1
Lisinopril And Hydrochlorothiazide Tablets	4	2.1	2.1
Patiromer	7	2.1	2.1
Pitavastatin Calcium	5	2.0	2.0
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	20	2.0	2.0
Tolvaptan	7	2.0	2.0
Empagliflozin	32	2.0	2.0
Insulin Degludec	11	2.0	2.0
Relugolix	11	1.9	1.9
Exenatide	24	1.9	1.9
Rasagiline Mesylate	5	1.9	1.9
Nilotinib	13	1.8	1.8
Interferon Beta-1A	82	1.8	1.8
Insulin Glargine	96	1.6	1.6
Interferon Beta-1B	7	1.5	1.5
Umeclidinium Bromide And Vilanterol Trifenatate	6	1.5	1.5
Insulin Lispro	48	1.5	1.5
Travoprost	3	1.4	1.4
Tafamidis	4	1.4	1.4
Venetoclax	20	1.4	1.4
Agalsidase Beta	3	1.4	1.4
Ledipasvir And Sofosbuvir	6	1.3	1.3
Oral Semaglutide	22	1.2	1.2
Abiraterone Acetate	12	1.2	1.2
Ambrisentan	36	1.2	1.2
Ixekizumab	10	1.1	1.1
Ranibizumab	7	1.1	1.1
Pirfenidone	9	0.9	0.9
Romosozumab-Aqqg	3	0.9	0.9
Aflibercept	6	0.8	0.8
Pimavanserin Tartrate	7	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.